Health Care - Spark Newswire

1 minute read

Abbott Says Has Capacity And Supply To Support Demand For MCS Devices

Today, 7:57 PM

Abbott (NYSE:ABT) today announced the company has capacity and supply to effectively support the growing demand for mechanical circulatory support (MCS) devices for the effective treatment of advanced heart failure

ABT

4 minute read

June SPAC Merger Vote Calendar: A Look At Upcoming Votes And Stocks To Watch

By Chris Katje

Today, 7:57 PM

June just started and the month is already looking busy for SPAC merger votes.

AACQ

2 minute read

Myocarditis Cases Probably Linked to Pfizer COVID-19 Vaccine, Says Israel Health Ministry: Reuters

By Vandana Singh

Today, 7:57 PM

Israel’s Health Ministry has reportedly found the small number of heart inflammation cases, observed mainly in young men who…

BNTX

2 minute read

US NIH Initiates Trial to Assess Mix-Match of COVID-19 Vaccine Booster Shots: CNBC

By Vandana Singh

Today, 7:57 PM

The National Institutes of Health (NIH) has started an early-stage clinical trial to assess what happens when a…

BNTX

1 minute read

Progenity to Close Genetic Test Services, Focus Shifts to Therapeutics

By Vandana Singh

Today, 7:57 PM

Women’s health diagnostic firm, Progenity Inc (NASDAQ: PROG), will close its genetics laboratory as part of a strategic transformation that emphasizes its drug…

PROG

2 minute read

Protalix Shares Hits 52-Week Low After Adverse Event Reported In Fabry Disease Trial With PRX-102

By Vandana Singh

Today, 7:57 PM

Protalix BioTherapeutics Inc (NYSE:PLX) and Chiesi Farmaceutici S.p.A. have provided an update on the clinical development of pegunigalsidase alfa (PRX–102) for the…

PLX

1 minute read

Lilly’s Olumiant Found to Lower Pain In Late-Stage Rheumatoid Arthritis Trial

By Vandana Singh

Today, 7:57 PM

Eli Lilly And Co (NYSE:LLY) has reported posthoc analyses data from the Phase 3 RA-BEAM study that showed Olumiant 4mg (baricitinib)…

ABBV

1 minute read

Almost Half of Crohn’s Disease Patients Achieved Endoscopic Response After One Year of Maintenance Treatment with AbbVie’s Risankizumab

By Vandana Singh

Today, 7:57 PM

AbbVie Inc (NYSE: ABBV) has announced positive top-line results from the Phase 3 maintenance study, FORTIFY, showing Skyrizi (risankizumab) achieved the co-primary endpoints of endoscopic response and clinical remission at one year in Crohn's disease.

ABBV

4 minute read

Big Tech Is More Important Than Ever With Alphabet Even Reaching New Horizons

By IAM Newswire

Today, 7:57 PM

With the latest earnings, it became clear that the pandemic push was just the beginning for Big Tech as Apple (NASDAQ: AAPL), Google owner Alphabet (NASDAQ: GOOG), Amazon (NASDAQ:

AAPL

1 minute read

Bristol Myers’ Opdivo-Yervoy Combo Approved In Europe, Canada For Malignant Pleural Mesothelioma

By Vandana Singh

Today, 7:57 PM

The regulatory authorities in Europe and Canada have approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment…

BMY